Search
SER-100
go.drugbank.com/drugs/DB16013InvestigationalSER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension).
Mericitabine
go.drugbank.com/drugs/DB12045InvestigationalMericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies. … PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication.
Fenbufen
go.drugbank.com/drugs/DB08981ApprovedFenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis.
Pacmilimab
go.drugbank.com/drugs/DB18873InvestigationalPacmilimab is under investigation in clinical trial NCT04596150 (Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer).
Teropavimab
go.drugbank.com/drugs/DB18916InvestigationalTeropavimab is under investigation in clinical trial NCT05729568 (A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
vCP2292
go.drugbank.com/drugs/DB19292InvestigationalAre in Remission). … vCP2292 is under investigation in clinical trial NCT01982487 (Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who
Efizonerimod alfa
go.drugbank.com/drugs/DB15390InvestigationalEfizonerimod alfa is under investigation in clinical trial NCT02221960 (A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors).
Amcipatricin
go.drugbank.com/drugs/DB12333InvestigationalIn preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. … SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models.
Fasedienol
go.drugbank.com/drugs/DB04968InvestigationalPH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.